• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Pharvaris N.V.

    Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris to Host Virtual Investor Event on October 23, 2024
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Presents Data at the Bradykinin Symposium 2024
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Announces Annual Meeting of Shareholders
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Announces Extraordinary Meeting of Shareholders
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris to Present at the WSAAI Annual Meeting 2024
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Pharvaris to Present at the GA²LEN UCARE Conference 2023
    From Pharvaris N.V.
    Via GlobeNewswire
    Tickers PHVS
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.